Our Promise is our north star for ourselves, patients, and society. It builds upon our history of forging life-altering scientific breakthroughs and reminds us that we are on a bolder quest than ever before - to be courageous changemakers in solving the world’s most complex health challenges and improving the lives of all patients. http://spr.ly/6049V62k7
About us
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation and diverse community around the issues we are passionate about. To that end, we remove profanity, content that contains credible threats or hate speech, content that is aimed at private individuals, personal information meant to harass someone, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
- Website
-
http://www.gene.com
External link for Genentech
- Industry
- Biotechnology Research
- Company size
- 10,001 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 1976
- Specialties
- Oncology, Immunology, Disorders of Tissue Growth and Repair, Neuroscience and Infectious Disease, Metabolism, and Ophthalmology
Locations
-
Primary
Get directions
1 Dna Way
South San Francisco, California 94080, US
-
Get directions
1000 New Horizons Way
Vacaville, California 95688, US
-
Get directions
1 Antibody Way
Oceanside, California 92056, US
-
Get directions
4625 NE Brookwood Pkwy
Hillsboro, Oregon 97124, US
Employees at Genentech
Updates
-
Through our Advancing Inclusive Research (AIR) Site Alliance, we collaborate and innovate with partners working to set the gold standard for diverse and inclusive clinical research. As we celebrate the Site Alliance’s three-year anniversary, hear from one of our site champions Dr. Alan Wagner, and co-leads Meg McKenzie, Principal, Patient Inclusion and Health Equity, and Ruma Bhagat, Portfolio Leader, Health Equity and Population Sciences, as they reflect on the initiative’s impact to date: http://spr.ly/6048cHg7G
-
On #NationalInternDay we’re shining a light on the 300 outstanding interns who have brought innovative thinking and fresh perspectives to Genentech this summer. Over the past few months, we've hosted 17 events for interns focused on professional development, community impact, and social networking, drawing over 900 total attendees. Today we're capping it all off with an on-campus Intern Appreciation Day event. Thank you to everyone in our 2024 summer intern class – your curiosity and enthusiasm is uplifting, and we’re all the better for it!
-
-
Since launching three years ago, our Advancing Inclusive Research (AIR) Site Alliance has made a real-world impact for communities who have been historically underrepresented and excluded from clinical research. From dismantling barriers that prevent people of color from participating, to enhancing cultural humility in care delivery, we’re proud to reflect on the impact of this work to foster community trust and advance inclusive research. Learn more about the lessons we’ve learned along the way and what’s next: http://spr.ly/6049cHgvz
-
How are we redefining the future of ophthalmology? Chris Brittain, our SVP and Global Head of Ophthalmology Product Development, shares his insights on treating retinal diseases that can cause blindness if left untreated and his perspective on our innovative pipeline that leverages AI, #CellTherapy and more to personalize patient care. Hear from him below.
-
We’re constantly exploring new ways to deliver medicines that can help alleviate patient burden from retinal diseases. Shamika Gune, MD, our Group Medical Director, shares more about our #innovation with the Port Delivery Platform, which offers an alternative to routine eye injections.
-
We are dedicated to advancing treatments for vision-threatening retinal diseases through cutting-edge research. Hear from Chris Brittain, our SVP and Global Head of Ophthalmology Product Development, on how our continued dedication to innovation helps patients preserve their vision and improve the treatment experience.
-
New two-year data about the efficacy and safety of our unique therapeutic approach that may provide diabetic macular edema (DME) and diabetic retinopathy (DR) patients with an alternative to regular eye injections were presented at this year's ASRS – American Society of Retina Specialists meeting. Learn more about these results and our commitment to helping people with diabetic eye diseases prevent #VisionLoss: http://spr.ly/6045iljDR #EyeHealth
-
At #ASRS2024, we presented data on our treatments for the leading causes of blindness, including diabetic macular edema (DME). Levi Garraway, our Chief Medical Officer and Head of Global Product Development, highlights our work to address #VisionLoss. Learn more here: http://spr.ly/6046iw0Tr
ASRS 2024: Levi Garraway, M.D., PH.D
-
New long-term data from the RHONE-X trial of DME patients treated with our bispecific antibody showed sustained and robust retinal drying and vision improvements. Learn more about these results, which were presented at this year’s #ASRS2O24, and how we are continuing to advance science for people living with #DiabeticEyeDisease: http://spr.ly/6043iguA9